IP Library Granted Patent US 11,260,067
Granted Patent B2
US 11,260,067 · App. 16/615,903 · Granted Mar 1, 2022

Methods and compositions for decreasing concentrations of detrimental proteolytic metabolites, treating health disorders, and/or promoting health benefits in infants or young children

Inventors: Norbert Sprenger (Savigny, CH); Florence Rochat (Montreux, CH); Laurent Favre (Carrouge, CH)
Assignee: Societe des Produits Nestle S.A.
A61K31/702A61K9/0095A61P1/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,260,067
App. No.
16/615,903
Granted
Mar 1, 2022
Kind
B2
Abstract

The present invention relates to a nutritional composition comprising at least two human milk oligosaccharides, for use to decrease the concentration of detrimental proteolytic metabolites (e.g. branched short chain fatty acids) in the digestive tract in an infant or a young child.

Claims (14)

1. A method of decreasing a concentration of detrimental proteolytic metabolites comprising a branched short chain fatty acid (SCFA) selected from the group consisting of isobutyrate, isovalerate, 2-methyl butyrate, and combinations thereof in a digestive tract in an infant or a young child in need thereof by at least 5% in comparison to a production in the digestive tract obtained with another nutritional composition comprising no human milk oligosaccharides, the method comprising administering to the infant or young child a nutritional composition comprising at least two human milk oligosaccharides in a total amount of from 0.1 to 10 wt % of the nutritional composition and a hydrolyzed protein, the at least two human milk oligosaccharides comprising at least 2′-fucosyllactose (2′FL) and lacto-N-neotetraose (LNnT).

2. The method according to claim 1 , wherein the at least two human milk oligosaccharides further comprise sialylated oligosaccharides.

3. The method according to claim 1 , wherein the nutritional composition further comprises a fucosylated oligosaccharide selected from the group consisting of 3′ fucosyllactose, difucosyllactose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-fucohexaose, lacto-N-difucohexaose I, fucosyllacto-N-hexaose, fucosyllacto-N-neohexaose I, fucosyllacto-N-neohexaose II, difucosyllacto-N-hexaose I, difucosyllacto-N-neohexaose I, difucosyllacto-N-neohexaose II, fucosyl-para-Lacto-N-hexaose, and combinations thereof.

4. The method according to claim 3 , wherein the fucosylated oligosaccharide comprises difucosyllactose (DFL or DiFL).

5. The method according to claim 1 , wherein the nutritional composition further comprises lacto-N-tetraose (LNT).

6. The method according to claim 1 , wherein the nutritional composition comprises a sialylated oligosaccharide selected from the group consisting of 3′ sialyllactose (3SL), 6′ sialyllactose (6SL) and combinations thereof.

7. The method according to claim 1 , wherein the at least two human milk oligosaccharides further comprise one human milk oligosaccharide selected from the group consisting of DFL, LNT, 3SL, 6SL, and combinations thereof.

8. The method according to claim 1 , wherein the nutritional composition comprises at least six human milk oligosaccharides 2′FL, DFL, LNnT, LNT, 3SL and 6SL.

9. The method according to claim 1 , wherein the concentration of detrimental proteolytic metabolites in the digestive tract is decreased with the diversity of the at least two human milk oligosaccharides present in the nutritional composition.

10. The method according to claim 1 , wherein the at least two human milk oligosaccharides are present in a total amount of from 0.5 to 7 wt % of the nutritional composition.

11. The method according to claim 1 , wherein the nutritional composition is in a form selected from the group consisting of an infant formula, a starter infant formula, a follow-on or follow-up infant formula, a baby food, an infant cereal composition, a fortifier and a supplement.

12. A method of treating or reducing a risk of allergies by decreasing a concentration of detrimental proteolytic metabolites comprising a branched short chain fatty acid (SCFA) selected from the group consisting of isobutyrate, isovalerate, 2-methyl butyrate, and combinations thereof in an infant or young child in need thereof by at least 5% in comparison to a production in the digestive tract obtained with another nutritional composition comprising no human milk oligosaccharides, the method comprising administering to the infant or young child a nutritional composition comprising at least two human milk oligosaccharides in a total amount of from 0.1 to 10 wt % of the nutritional composition and a hydrolyzed protein, the at least two human milk oligosaccharides comprising at least 2′FL and LNnT.

13. The method of claim 1 , wherein the nutritional composition is a growing-up milk.

14. The method of claim 1 , wherein the infant or young child was born by C-section.

Assignments (2)
MERGER Recorded Oct 27, 2021
From: NESTEC S.A.
To: SOCIETE DES PRODUITS NESTLE S.A.
Reel/Frame 057927/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2021
From: SPRENGER, NORBERT; ROCHAT, FLORENCE; FAVRE, LAURENT
To: NESTEC S.A.
Reel/Frame 057927/0873 →
Priority Claims (1)
EP 17172644 · May 24, 2017 · regional
Continuity (1)
Related Publication 20200138836A1 · May 7, 2020